Croda International PLC · LSE:CRDA

Croda International — Q3 2014 Earnings Presentation

18 slides from Croda International's earnings presentation, November 2014

  1. Slide 1: Croda International Plc Q3 IMS November 2014

    Slide 1: Croda International Plc Q3 IMS November 2014

    Croda International Plc Q3 IMS November 2014

  2. Slide 2: Underlying progress accelerates in Q3

    Slide 2: Underlying progress accelerates in Q3

    Underlying progress accelerates in Q3  Constant currency turnover up 4.0%  Consumer Care +4.2%  Performance Technologies +8.2%  Pharma grade Omega 3 sales to PAR commence  Strong underlying growth in New and Protected Products (NPP)  Growth in all major geographies apart from Latin America  S

  3. Slide 3: Strategic Priorities

    Slide 3: Strategic Priorities

    Strategic Priorities  Consistent top and bottom line growth  Increase the proportion of total sales that are patented  Constant innovation and relentless investment 3

  4. Slide 4: Consistent top and bottom line growth

    Slide 4: Consistent top and bottom line growth

    Consistent top and bottom line growth  Consumer Care  Performance Technologies  4.2% growth 1  8.2% growth 1  Strong Health Care performance  Growth in all markets ahead of target  Improving trend in Personal Care  Strong performance in Lubricants  Crop Care stable  Healthy growth in emerg

  5. Slide 5: Increasing the proportion of sales that are patented

    Slide 5: Increasing the proportion of sales that are patented

    Increasing the proportion of sales that are patented % NPP Consumer Care  New and Protected Products (NPP) 40 underlying growth 12% for the group 30 20  Helping our customers create 10 valuable brands that meet unmet 0 needs 2011 2012 2013 2014  IRB, Acrylic Polymers, Arizona % NPP Performance Te

  6. Slide 6: Constant innovation and relentless investment

    Slide 6: Constant innovation and relentless investment

    Constant innovation and relentless investment UK France New “Customer USA Training Center” Expanded Japan R&D Center New applications Mexico China lab and sales office India in Shanghai New “Customer Singapore Training Center” and Sales Office Expanded R&D with New “Claims Testing Brazil Hub” and Sa

  7. Slide 7: Investing in new technology – Pharma active ingredient

    Slide 7: Investing in new technology – Pharma active ingredient

    Investing in new technology – Pharma active ingredient  Ultra high purity Pharma grade Omega-3  FDA clearance to supply from GMP compliant facility in UK FDA approved technology, Leek  Access to generic Omacor/ Lovaza® market  Indicated for the treatment of elevated blood triglycerides Partnerin

  8. Slide 8: New global customer facing organisation

    Slide 8: New global customer facing organisation

    New global customer facing organisation Creation of 3 global business groups  Personal Care  Health Care & Crop Care  Performance Technologies & Industrial Chemicals (PTIC)  Combining Sales, Marketing and Research by sector in dedicated global teams  Full Executive Committee accountability with

  9. Slide 9: Executive Committee Responsibility

    Slide 9: Executive Committee Responsibility

    Executive Committee Responsibility Responsibilities Kevin Gallagher Sandra Breene Maarten Heybroek Personal Care Health & Crop PT/ IC Key benefits of change  Fully aligned with our customers’ needs  Separating Personal Care from Health and Crop will provide sharper, tailored management and strateg

  10. Slide 10: 2014 Q3 results

    Slide 10: 2014 Q3 results

    2014 Q3 results  Basis of preparation  Unless otherwise stated, all profit and earnings numbers are stated before acquisition costs and goodwill amortisation

  11. Slide 11: Q3 sales by segment

    Slide 11: Q3 sales by segment

    Q3 sales by segment £m 2014 2013 Reported Constant growth currency Consumer Care 140.7 145.4 -3.2% +4.2% Performance Technologies 90.1 89.5 +0.7% +8.2% Industrial Chemicals 28.2 33.0 -14.5% -8.7% Total turnover 259.0 267.9 -3.3% +4.0%  In Q3, both CC and PT saw strong underlying growth despite abse

  12. Slide 12: Sales trends – positive momentum

    Slide 12: Sales trends – positive momentum

    Sales trends – positive momentum Q1 Q2 Q3 YTD Consumer Care -0.6% +0.6% +4.2% +1.3% Performance +3.7% +2.7% +7.9% +4.5% Technologies Industrial Chemicals +2.7% -5.7% -12.3% -5.7% Underlying sales +1.3% +0.5% +3.4% +1.6% Acquisitions +1.6% +1.3% +0.6% +1.2% Constant +2.9% +1.8% +4.0% +2.8% currency C

  13. Slide 13: Consumer Care

    Slide 13: Consumer Care

    Consumer Care £m Q3 2014 2013 Growth CC Sales 160 (£m) Turnover 140.7 145.4 -3.2% +4.2% 120 Operating 80 42.2 45.7 -7.7% -1.5% profit 40 ROS 30.0% 31.4% 0 Q1 Q2 Q3 Q4  4.2% underlying sales growth  Strong underlying growth in Health Care driven by PAR 60 EBIT 50  Crop saw modest underlying growth

  14. Slide 14: Performance Technologies

    Slide 14: Performance Technologies

    Performance Technologies 120 £m Q3 2014 2013 Growth CC Sales 100 (£m) Turnover 90.1 89.5 +0.7% +8.2% 80 60 Operating 15.4 14.0 +10.0% +14.3% 40 profit 20 ROS 17.1% 15.6% 0 Q1 Q2 Q3 Q4  Very strong performance despite being overweight 20 US/Europe and lack of inflation EBIT  Asia sales particularly

  15. Slide 15: Industrial Chemicals

    Slide 15: Industrial Chemicals

    Industrial Chemicals 35 £m Q3 2014 2013 Growth CC Sales 30 (£m) 25 Turnover 28.2 33.0 -14.5% -8.7% 20 Operating 15 0.5 2.4 -79.2% --75.0% 10 profit 5 ROS 1.8% 7.3% 0 Q1 Q2 Q3 Q4  Weak commodity markets and currency headwinds put 5 pressure on margins for by-products EBIT (£m) 4  Reduced levels of

  16. Slide 16: Q3 Pre-tax profit

    Slide 16: Q3 Pre-tax profit

    Q3 Pre-tax profit £m 2014 2013 Growth CC Total EBIT 58.1 62.1 -6.4% -0.8% ROS 22.4% 23.2% Financing (3.0) (3.4) Pre-tax profit 55.1 58.7 -6.1% -0.2%  Reported EBIT reduced by £5.5m due to currency effects  Translation £3.5m and transaction £2.0m  only translation effects included in constant curr

  17. Slide 17: Cash flow and net debt

    Slide 17: Cash flow and net debt

    Cash flow and net debt  Strong cash generation in Q3  Net debt increases by only £18m despite paying £42m in dividends and £16m capex  Net debt stands at £220m * As per loan covenant calculations, rolling 12 months 17

  18. Slide 18: Summary and outlook

    Slide 18: Summary and outlook

    Summary and outlook  Visibility limited and market trends remain difficult to predict  Q4 always our lowest sales quarter  Christmas shutdowns at many customers  Encouraged by underlying momentum building in Q3  6 out of 8 core markets in target sales growth range in Q3  All 8 core markets saw

Source: Internet Archive copy of croda.com

More decks from Croda International PLC

All 37 Croda International decks